期刊文献+

Immunotherapy prototype Mark 3.0 model in primary liver cancer:adding locoregional stereotactic therapy and prognostic factors classification management 被引量:1

原文传递
导出
摘要 Immune checkpoint inhibitors(ICIs)like programmed cell death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitor have shown considerable efficacy in several important cancers including primary liver cancer(PLC)like hepatocellular carcinoma and cholangiocarcinoma.However,only some patients with PLC will benefit,so combination therapy and biomarker classification detected by next-generation sequencing or immunohistochemistry are very important.Herein,we briefly summarize ICI-based therapies and stratify these evolving therapies for advanced PLC into three stages of immunotherapies Mark(Mk.)1.0,2.0,and 3.0.We illustrated the significance of ICI monotherapy(Mk.1.0),offering combinational approaches with traditional strategies(Mk.2.0)and additional locoregional therapy(Mk.3.0)to achieve longer survival and even meet the“No Evidence of Disease”status.We also highlight the importance of biomarkers and prognostic factors for patients with advanced PLC treated with ICI-based therapies.Multidisci-plinary team management should be investigated and collaborated closely to manage adverse events and sequential therapy suggestions for patients.
出处 《Medical Review》 2022年第6期547-552,共6页 医学评论(英文)
基金 supported by National High Level Hospital Clinical Research Funding[2022-PUMCH-B-128],CAMS Innovation Fund for Medical Sciences(CIFMS)[2022-I2M-C&T-A-003][2021-I2M-1-061][2021-I2M-1-003] CSCO-hengrui Cancer Research Fund[Y-HR2019-0239][Y-HR2020MS-0415][Y-HR2020QN-0414] CSCO-MSD Cancer Research Fund[Y-MSDZD2021-0213]and National Ten-Thousand Talent Program.
  • 相关文献

同被引文献14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部